In this study, it was confirmed that these melanoma cells use the TIMP1/CD63/β1-integrin complex to induce the activation of signaling pathways involving NF-κB and ERK precisely to promote resistance to Vemurafenib [98]. The gene discussed is TIMP1; the disease is melanoma.